ClinicalTrials.gg
CompletedNCT04693195BLUEPRINTUpdated Oct 17, 2022

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

A Phase 2 interventional study of BLU-5937 and Placebo in Chronic Pruritus and Atopic Dermatitis, sponsored by Bellus Health Inc. - a GSK company. Completed at 33 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-10-17.

Sponsored by Bellus Health Inc. - a GSK company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2022.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Dermatitis, Atopic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · GlaxoSmithKline.

Enrollment
6th of 18
142 · median 42
Started
2020
the only one that year
Phase 2
8 of 19
none open now
Registered
14th of 19
by date

Among the 19 studies in Dermatitis, Atopic by GlaxoSmithKline, this one is the 6th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 2, and was the 14th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 19 studies in Dermatitis, Atopic by GlaxoSmithKline is open now. The open studies under Dermatitis, Atopic, anywhere →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Dermatitis, Atopic by GlaxoSmithKline as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel design study of BLU-5937 for the treatment of chronic pruritus in adult subjects with atopic dermatitis (AD).

Read the detailed description

The study will consist of a 37-day Screening period (including a 7-day Run-In period), a 4-week Treatment period followed by a Follow-Up visit approximately 2 weeks after the last dose of study drug.

03

Conditions studied

  • Chronic Pruritus
  • Atopic Dermatitis

Browse trials for

Keywords

  • BLU-5937
  • Chronic Pruritus
  • Atopic Dermatitis
  • P2X3 receptor antagonist
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to participate and is capable of giving
  • Clinically confirmed diagnosis of active AD with at least a 6-month history of AD
  • Chronic pruritus related to AD for at least 3 months
  • Moderate to severe itch associated with mild to moderate AD
  • Female of must agree to use a highly effective method during the study and until at least 4 weeks after the last study drug administration

Exclusion criteria

Exclusion Criteria:

  • History of skin disease or presence of skin condition that would interfere with the study assessments
  • Clearly defined etiology for pruritus other than AD, including but not limited to: urticaria, psoriasis, or other non-atopic dermatologic conditions, hepatic or renal disease, psychogenic pruritus, drug reaction, uncontrolled hyperthyroidism, and infection
  • Presence of any acute skin condition other than AD which may risk inducing a pruritus flare/worsening during the course of the study, including but not limited to: impetigo, active herpes simplex infection, or allergic contact dermatitis
  • Subject is >65 years of age and has developed pruritus at age of ≥50 years
  • History of cancer or lymphoproliferative disease within 5 years with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix
  • Known history of, or active, parasitic infection, including skin parasites such as scabies within 12 months prior to Screening
  • Known history of chronic infectious disease (e.g. , , or [HIV])
  • Known history of drug or alcohol abuse in the last year
  • Previous participation in a BLU-5937 trial
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    BLU-5937 oral tablet

    Eligible participants will receive BLU-5937 twice a day (BID) orally for 4 weeks.

    Drug: BLU-5937

  • Placebo comparator
    Placebo oral tablet

    Eligible participants will receive matching Placebo BID orally for 4 weeks.

    Drug: Placebo

Interventions

  • Oral administration of BLU-5937 tablets

  • DrugPlacebo

    Oral administration of matching placebo for BLU-5937 tablets

06

What researchers measure

Primary outcomes

  1. Change from baseline in weekly mean Worst Itch Numeric Rating Scale (WI-NRS) score

    Assessed by Worst Itch Numeric Rating Scale \[WI-NRS\] The WI-NRS is a single item questionnaire assessing the patient-reported severity of itch at its most intense during the previous 24-hour period on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'the worst itch imaginable'. Higher scores indicate worse severity.

    Time frame: Week 4

Secondary outcomes

  1. Proportion of subjects achieving at least 4-point improvement from baseline in weekly mean Worst Itch Numeric Rating Scale (WI-NRS) score

    Assessed by Worst Itch Numeric Rating Scale \[WI-NRS\] The WI-NRS is a single item questionnaire assessing the patient-reported severity of itch at its most intense during the previous 24-hour period on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'the worst itch imaginable'. Higher scores indicate worse severity.

    Time frame: Week 4

  2. Change from baseline in Average Itch Numeric Rating Scale (AI-NRS) score

    Assessed by Average Itch Numeric Rating Scale \[AI-NRS\] The AI-NRS is a single item questionnaire assessing the patient-reported severity of itch overall (on average) during the previous 24-hour period on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'the worst itch imaginable'. Higher scores indicate worse severity.

    Time frame: Week 4

  3. Change from baseline in Itching Quality of Life Survey (ItchyQOL)

    Assessed by Itching Quality of Life Survey \[ItchyQOL\] The ItchyQOL is a 22-item questionnaire assessing the pruritus-specific disease burden on 3 domains: symptoms, functions and emotions. The responses to the frequency items are scored on a 1 (never) to 5 (all the time) scale. The recall period in ItchyQoL is the past week. Higher scores indicate a more adverse impact on quality of life.

    Time frame: Week 4

  4. Proportion of subjects in each category of the Patient Global Impression of Change (PGIC) questionnaire

    Assessed by Patient Global Impression of Change \[PGIC\] The PGIC consists of 1 self-administered item that assesses the subject's impression of change in the severity of pruritus using a 7-point scale from 1 (very much improved) to 7 (very much worse). Higher scores indicate a worsening of the severity.

    Time frame: Week 4

07

Study locations

33 sites
  • Bellus Health Investigational Site #28
    Phoenix, Arizona 85032, United States
  • Bellus Health Investigational Site #10
    Scottsdale, Arizona 85254, United States
  • Bellus Health Investigational Site #23
    Beverly Hills, California 90212, United States
  • Bellus Health Investigational Site #33
    Encinitas, California 92024, United States
  • Bellus Health Investigational Site #27
    Fountain Valley, California 92708, United States
  • Bellus Health Investigational Site #35
    San Diego, California 92123, United States
  • Bellus Health Investigational Site #15
    Hialeah, Florida 33012, United States
  • Bellus Health Investigational Site #32
    Margate, Florida 33063, United States
  • Bellus Health Investigational Site #16
    Miami, Florida 33125, United States
  • Bellus Health Investigational Site #19
    Miami, Florida 33136, United States
  • Bellus Health Investigational Site #17
    Sweetwater, Florida 33172, United States
  • Bellus Health Investigational Site #24
    Savannah, Georgia 31406, United States
  • Bellus Health Investigational Site #13
    Owensboro, Kentucky 42301, United States
  • Bellus Health Investigational Site #38
    Baton Rouge, Louisiana 70809, United States
  • Bellus Health Investigational Site #45
    Covington, Louisiana 70433, United States
  • Bellus Health Investigational Site #18
    New Orleans, Louisiana 70115, United States
  • Bellus Health Investigational Site #36
    Minneapolis, Minnesota 55402, United States
  • Bellus Health Investigational Site #22
    Portsmouth, New Hampshire 03801, United States
  • Bellus Health Investigational Site #34
    New York, New York 10075, United States
  • Bellus Health Investigational Site #14
    High Point, North Carolina 27262, United States
  • Bellus Health Investigational Site #29
    Norman, Oklahoma 73071, United States
  • Bellus Health Investigational Site #37
    Newtown Square, Pennsylvania 19073, United States
  • Bellus Health Investigational Site #41
    Rapid City, South Dakota 57702, United States
  • Bellus Health Investigational Site #12
    Austin, Texas 78759, United States
  • Bellus Health Investigational Site #31
    College Station, Texas 77845, United States
  • Bellus Health Investigational Site #40
    San Antonio, Texas 78213, United States
  • Bellus Health Investigational Site #11
    San Antonio, Texas 78229, United States
  • Bellus Health Investigational Site #25
    Seattle, Washington 98101, United States
  • Bellus Health Investigational Site #44
    Chicoutimi, Quebec G7H 7Y8, Canada
  • Bellus Health Investigational Site #20
    Montreal, Quebec H2X 2V1, Canada
  • Bellus Health Investigational Site #43
    Quebec City, Quebec G1N 4V3, Canada
  • Bellus Health Investigational Site #39
    Quebec city, Quebec G1W 4R4, Canada
  • Bellus Health Investigational Site #42
    Sherbrooke, Quebec J1L 0H8, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Oct 2021, 9 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 9 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2020
First posted
Jan 5, 2021
StartActual
Dec 9, 2020
Primary completionActual
Oct 4, 2021
CompletionActual
Oct 12, 2021
Results delay requested
Sep 30, 2022
Last update
Oct 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04693195
Responsible party
Sponsor
First posted
Jan 5, 2021
Start date
Dec 9, 2020
Primary completion
Oct 4, 2021
Completion
Oct 12, 2021
Last update
Oct 17, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BLU-5937

Start the discussion